A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the safety and efficacy of DE-101 to improve the signs and symptoms in dry-eye disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen Inc.

Criteria

Inclusion Criteria:

• Individuals considered for entry into the study will be of either sex and any race who have:

• a confirmed diagnosis of dry eye,

• are willing to use no ocular treatments during the study other than study medication,

• have a corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity score of +0.7 logarithm of the minimum angle of resolution (logMAR) or better in each eye,

• will not use contact lenses during the study,

• Females of child-bearing potential must have a negative urine pregnancy test and be willing to use an acceptable method of contraception to be eligible for, and continue participation in, the study,

• 18 years of age or older,

• able to understand and provide written informed consent

Exclusion Criteria:

• Subjects with any of the following are not eligible to participate in the study:

• Fluorescein corneal staining or conjunctival staining that is too severe

• Conditions requiring the use of ophthalmic prescription or over the counter medications during the study (except for study medications)

• Any type of current punctal occlusion including punctal plugs, intracanalicular punctal plugs or cauterized puncta

• Any type of ocular surgery within 90 days prior to Visit 1 (Day 1)

• Known history of Steven-Johnson's syndrome, Riley-Day syndrome, and/or ocular pemphigoid

• Ocular(including lid)disease/abnormality that may interfere with the study

• Corneal transplant in either eye, at any time prior to enrollment in the study

• Laser refractive surgery less than one year prior to Visit 1 (Day 1)

• Conditions requiring the use of any systemic medication that is not ongoing at a stable dosage for at least 30 days prior to Visit 1 (Day 1)

• Application of isotretinoin within 30 days prior to Visit 1 (Day 1)

• Known allergy or sensitivity to any of the study medication components

• Uncontrolled systemic conditions or other conditions which would confound the study evaluations or endanger the safety of the subject

• A woman who is pregnant, nursing, or planning a pregnancy

• Participation in another investigational drug or vaccine trial, or participation in such a trial within 30 days prior to Visit 1 (Day 1)